Program
PTM Cilofexor Dose A
Also written as “PTM Cilofexor Dose B”.
Its studies are mostly in Liver Cirrhosis, Biliary, led by Gilead Sciences.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciences | 11 open or running | phase 2since Sep 21, 2026 | Sep 21, 2026 | Dec 2028phase 2 · NCT07841977 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 21, 2026First study: phase 2 study in Liver Cirrhosis, BiliaryFirst studyNCT07841977 · 132 planned · United States
Ahead
- Dec 2028Primary completion: phase 2 study in Liver Cirrhosis, BiliaryNCT07841977
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07841977Liver Cirrhosis, Biliary · United States | 2 | Recruiting | Dec 2028 | 132 |
How it is read
Names in the registry
- “PTM Cilofexor Dose A”, 1 entry
- “PTM Cilofexor Dose B”, 1 entry
Conditions, from the studies’ own filings
- Liver Cirrhosis, Biliary, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.